Abbott eyes $20B bond sale to fund purchase of Exact Sciences - report
Seeking Alpha News (Mon, 23-Feb 11:10 AM ET)
Abbott Laboratories Streamlines Governance With Smaller Board
TipRanks (Fri, 20-Feb 4:57 PM ET)
Exact Sciences Stockholders Approve Acquisition by Abbott
Business Wire (Fri, 20-Feb 4:05 PM ET)
Abbott Laboratories declares $0.63 dividend
Seeking Alpha News (Fri, 20-Feb 12:29 PM ET)
BTIG Sticks to Their Buy Rating for Abbott Laboratories (ABT)
TipRanks (Fri, 20-Feb 12:06 PM ET)
Abbott declares 409th consecutive quarterly dividend
PRNewswire (Fri, 20-Feb 11:39 AM ET)
China drug licensing deals surge nearly 10-fold in value since 2021
Seeking Alpha News (Thu, 19-Feb 1:31 PM ET)
PRNewswire (Fri, 6-Feb 8:00 AM ET)
Abbott Projects Double-Digit EPS Growth for 2026 on Strength in Medical Devices
Market Chameleon (Thu, 22-Jan 2:58 AM ET)
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
PRNewswire (Thu, 22-Jan 7:30 AM ET)
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Abbott Laboratories trades on the NYSE stock market under the symbol ABT.
As of February 24, 2026, ABT stock price declined to $114.58 with 7,263,093 million shares trading.
ABT has a beta of 0.36, meaning it tends to be less sensitive to market movements. ABT has a correlation of 0.08 to the broad based SPY ETF.
ABT has a market cap of $199.42 billion. This is considered a Large Cap stock.
Last quarter Abbott Laboratories reported $11 billion in Revenue and $1.50 earnings per share. This fell short of revenue expectation by $-338 million and met earnings estimates .
In the last 3 years, ABT traded as high as $141.23 and as low as $89.67.
The top ETF exchange traded funds that ABT belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
ABT has underperformed the market in the last year with a return of -13.3%, while the SPY ETF gained +15.8%. In the last 3 month period, ABT fell short of the market, returning -10.1%, while SPY returned +4.6%. However, in the most recent 2 weeks ABT has outperformed the stock market by returning +3.2%, while SPY returned -1.0%.
ABT support price is $113.51 and resistance is $117.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABT shares will trade within this expected range on the day.